OLANZAPINE
Drug
Alkermes, Inc.
Total Payments
$9.5M
Transactions
3,793
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $7,396 | 5 | 0 |
| 2022 | $907,313 | 335 | 0 |
| 2021 | $631,034 | 381 | 0 |
| 2020 | $452,183 | 398 | 0 |
| 2019 | $3.0M | 844 | 0 |
| 2018 | $4.5M | 1,830 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.5M | 3,793 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | Alkermes, Inc. | $4.3M | 0 |
| A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to OLANZAPINE in Adults with Schizophrenia | Alkermes, Inc. | $3.9M | 0 |
| A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | Alkermes, Inc. | $915,855 | 0 |
| A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) | Alkermes, Inc. | $288,532 | 0 |
Top Doctors Receiving Payments for OLANZAPINE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Grand Rapids, MI | $9.5M | 3,793 |
Ad
Manufacturing Companies
- Alkermes, Inc. $9.5M
Product Information
- Type Drug
- Total Payments $9.5M
- Total Doctors 0
- Transactions 3,793
About OLANZAPINE
OLANZAPINE is a drug associated with $9.5M in payments to 0 healthcare providers, recorded across 3,793 transactions in the CMS Open Payments database. The primary manufacturer is Alkermes, Inc..
Payment data is available from 2018 to 2023. In 2023, $7,396 was paid across 5 transactions to 0 doctors.
The most common payment nature for OLANZAPINE is "Unspecified" ($9.5M, 100.0% of total).
OLANZAPINE is associated with 4 research studies, including "A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness" ($4.3M).